Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Cellular Adaptation IV: Dysplasia and Metaplasia

Cellular Adaptation IV: Dysplasia and Metaplasia

DysplasiaDysplasia refers to abnormal changes in the size, shape, and organization of mature cells, characterized by pleomorphism, nuclear abnormalities, and increased mitotic activity. It commonly affects epithelial tissues, including the cervix, gastrointestinal tract, respiratory mucosa, and endometrium. Although it may occur alongside hyperplasia, dysplasia is not a true adaptive response but a preneoplastic change with potential to progress to cancer.When confined above the basement...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.

American journal of hematology·2017

Same author

Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome.

American journal of hematology·2017

Same author

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.

Cancer·2017

Same author

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.

American journal of hematology·2017

Same author

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.

American journal of hematology·2017

Same author

Corrigendum: Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia.

Nature immunology·2017

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Progress in myelodysplastic syndromes.

Guillermo Garcia-Manero¹

¹Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. ggarciam@mdanderson.org

Clinical Lymphoma & Myeloma

|September 26, 2009

Summary

This summary is machine-generated.

Recent advancements have significantly improved the understanding and treatment of myelodysplastic syndromes (MDS). New therapies offer safer, more effective options to modify the natural history of these hematopoietic disorders.

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Related Experiment Videos

Last Updated: Jun 20, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Area of Science:

Hematology
Oncology
Internal Medicine

Background:

Myelodysplastic syndromes (MDS) are a complex group of hematopoietic stem cell disorders.
Significant progress has been made in understanding MDS over the last five years.
This includes advancements in classification, risk stratification, and supportive care.

Purpose of the Study:

To summarize recent key developments in the field of myelodysplastic syndromes.
To highlight new therapeutic opportunities for MDS patients.
To identify emerging challenges and future research directions in MDS.

Main Methods:

This review synthesizes information from recent scientific literature and conference proceedings.
It focuses on advancements presented at the Leukemia 2008, Fourth International Conference.
The review covers new classifications, scoring systems, supportive care, and novel treatments.

Main Results:

There has been an "explosion" in the understanding and classification of MDS.
New scoring systems and supportive care measures have been developed.
Effective treatments that can modify the natural history of MDS are now available.

Conclusions:

The field of MDS has seen substantial progress in the last five years.
New therapeutic strategies offer improved safety and efficacy for patients.
Continued research is crucial to address remaining challenges and optimize patient outcomes.